T-DXd followed by THP improved pCR in high-risk, early-stage HER2+ breast cancer in the phase 3 DESTINY-Breast11 trial.

ADRX-0706 has received FDA fast track designation for the treatment of metastatic or locally advanced squamous cell cervical ...

Treatment-related adverse effects were reported in 97.2% of heavily pretreated patients with uterine serous carcinoma taking ...

The FDA has granted accelerated approval to avutometinib (VS-6766) plus defactinib (VS-6063) for the treatment of adult ...

Use of the 1.5T Elekta Unity MR-Linac was associated with reduced rates of erectile dysfunction at 6, 12, and 18 months in ...

Oncology nurses can enhance endometrial cancer recovery by fostering strong social support networks and improving ...

The FDA approved the use of daratumumab and hyaluronidase-fihj (Darzalex Faspro) for patients who are newly diagnosed with ...

Infusion bays designed with nurse input provide patients the choice between privacy and community while allowing support from loved ones.

The FDA has approved a ready-to-dilute, multidose formulation of thiotepa (Tepylute) for use in breast and ovarian ...

Oncology nurses can encourage clinical trial enrollment for patients with anaplastic thyroid cancer, a rare and aggressive ...

The selective CDK2 inhibitor INX-315 has been given FDA fast track designation for use in CCNE1-amplified, platinum-resistant ...

Pediatric patients with high-risk neuroblastoma had significantly lower 5-year survival rates in induction and/or ...